Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||BMS-754807 + Midostaurin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BMS-754807||ALK Inhibitor 29 Aurka Inhibitors 25 Aurkb Inhibitors 20 IGF-1R Inhibitor 17 MET Inhibitor 56 TrkA Receptor Inhibitor 8||BMS-754807 is a multi-kinase inhibitor with activity against IGF-1R, insulin receptor, MET, ALK, TRKA, TRKB, AURKA, and AURKB, potentially resulting in decreased tumor cell proliferation (PMID: 25748921, PMID: 31433065).|
|Midostaurin||Rydapt||PKC412|CGP 41251||CSF1R Inhibitor 27 FLT3 Inhibitor 61 KIT Inhibitor 55 PKC alpha Inhibitor 6 PKC beta Inhibitor 6 PKC Inhibitor (Pan) 11 VEGFR2 Inhibitor 35||Rydapt (midostaurin) is a multi-kinase inhibitor with activity against FLT3, KIT, PDGFRB, KDR (VEGFR2) and PKC, with higher selectivity for conventional PKC isoforms, which induces cell cycle arrest and apoptosis (PMID: 12124173, PMID: 23127174, PMID: 15914319). Rydapt (midostaurin) is FDA approved for FLT3-mutant AML in combination with chemotherapy, and is approved for use in aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia as a single therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|